{'52WeekChange': 1.820513,
 'SandP52WeekChange': 0.0644362,
 'address1': '60 Jubilee Avenue',
 'address2': 'Milton Park',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.79,
 'askSize': 1800,
 'averageDailyVolume10Day': 1113475,
 'averageVolume': 3281803,
 'averageVolume10days': 1113475,
 'beta': 2.398879,
 'beta3Year': None,
 'bid': 8.78,
 'bidSize': 1100,
 'bookValue': 1.43,
 'category': None,
 'circulatingSupply': None,
 'city': 'Abingdon',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.5188,
 'dayLow': 8.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.61,
 'enterpriseToRevenue': 516.654,
 'enterpriseValue': 972860352,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '44 12 3543 0001',
 'fiftyDayAverage': 9.679143,
 'fiftyTwoWeekHigh': 13.4,
 'fiftyTwoWeekLow': 0.709,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 69915153,
 'forwardEps': -1.11,
 'forwardPE': -7.927928,
 'fromCurrency': None,
 'fullTimeEmployees': 383,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00204,
 'heldPercentInstitutions': 0.50738,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/adaptimmune.com',
 'longBusinessSummary': 'Adaptimmune Therapeutics plc, a clinical-stage '
                        'biopharmaceutical company, focuses on providing novel '
                        'cell therapies primarily to patients with solid '
                        "tumors in the United States. The company's specific "
                        'peptide enhanced affinity receptor T-cell platform '
                        'enables it to identify cancer targets. It is involved '
                        'in developing ADP-A2M10 that is in the phase I '
                        'clinical trials for the treatment of non-small cell '
                        'lung cancer (NSCLC), as well as urothelial, melanoma, '
                        'and head and neck cancers; ADP-A2M4 that is in phase '
                        'I clinical trial for solid tumor indication that '
                        'include urothelial, melanoma, head and neck, ovarian, '
                        'NSCLC, esophageal, gastric, synovial sarcoma, and '
                        'myxoid round cell liposarcoma cancers; and ADP-A2AFP '
                        'that is in phase I clinical trial for hepatocellular '
                        'carcinoma. The company has a strategic collaboration '
                        'and license agreement with GSK to research, develop, '
                        'and commercialize NY-ESO T-cell therapy; and '
                        'collaboration agreement with Noile-Immune Biotech '
                        'Inc. to develop SPEAR T-cells in combination with '
                        "Noile-Immune's PRIME technology. It also has a "
                        'co-development and co-commercialization agreement '
                        'with Universal Cells, Inc to bring new stem-cell '
                        'derived allogeneic T-Cell therapies to people with '
                        'cancer. Adaptimmune Therapeutics plc was founded in '
                        '2008 and is headquartered in Abingdon, the United '
                        'Kingdom.',
 'longName': 'Adaptimmune Therapeutics plc',
 'market': 'us_market',
 'marketCap': 1352419200,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_113495056',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -137920000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.44,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -9.8,
 'phone': '44 12 3543 0000',
 'previousClose': 9.31,
 'priceHint': 2,
 'priceToBook': 6.1538467,
 'priceToSalesTrailing12Months': 718.2258,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.5188,
 'regularMarketDayLow': 8.64,
 'regularMarketOpen': 9.44,
 'regularMarketPreviousClose': 9.31,
 'regularMarketPrice': 9.44,
 'regularMarketVolume': 784445,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 153684000,
 'sharesPercentSharesOut': 0.0242,
 'sharesShort': 3938034,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 558773,
 'shortName': 'Adaptimmune Therapeutics plc',
 'shortPercentOfFloat': None,
 'shortRatio': 1.46,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ADAP',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.258,
 'twoHundredDayAverage': 5.4289207,
 'volume': 784445,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.adaptimmune.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'OX14 4RX'}